Abbisko (HKG:2256) reported 322.5 million yuan in attributable profit for the six months ended June 30, up from the 216.9 million yuan in the year-ago period, according to a Hong Kong bourse filing Monday.
Shares of the biopharmaceutical company rose nearly 5% in recent Tuesday trade.
Diluted earnings of 0.51 yuan per share compared to the 0.32 yuan per share a year prior.
The firm generated 612.1 million yuan in the first six months of the year, rising from 497.3 million yuan a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.